StockMacro
Menu

PTC Therapeutics

$56.42 -17% in 6 monthsMarket cap $4.7B

PTCT on XNAS, Health Care, PTC Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue jumped 70% to $357.8M, but the stock is down 26% over twelve months.

  • BadTwelve-month revenue fell 35% to $1.2B and the company lost $106M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Industry
Pharmaceutical preparations (Health Care)
Employees
991
Website
ptcbio.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $357.8M, net loss $51.7M.
Quarter to 31 Dec 2021: revenue $165.2M, net income -$143.3MQuarter to 31 Dec 2021: revenue $165.2M, net income -$143.3MQuarter to 31 Mar 2022: revenue $148.7M, net income -$126.7MQuarter to 31 Mar 2022: revenue $148.7M, net income -$126.7MQuarter to 30 Jun 2022: revenue $165.5M, net income -$152.1MQuarter to 30 Jun 2022: revenue $165.5M, net income -$152.1MQuarter to 30 Sep 2022: revenue $217.1M, net income -$109.3MQuarter to 30 Sep 2022: revenue $217.1M, net income -$109.3MQuarter to 31 Dec 2022: revenue $167.4M, net income -$170.9MQuarter to 31 Dec 2022: revenue $167.4M, net income -$170.9MQuarter to 31 Mar 2023: revenue $220.4M, net income -$139.0MQuarter to 31 Mar 2023: revenue $220.4M, net income -$139.0MQuarter to 30 Jun 2023: revenue $213.8M, net income -$198.9MQuarter to 30 Jun 2023: revenue $213.8M, net income -$198.9MQuarter to 30 Sep 2023: revenue $196.6M, net income -$133.0MQuarter to 30 Sep 2023: revenue $196.6M, net income -$133.0MQuarter to 31 Dec 2023: revenue $307.1M, net income -$155.8MQuarter to 31 Dec 2023: revenue $307.1M, net income -$155.8MQuarter to 31 Mar 2024: revenue $210.1M, net income -$91.6MQuarter to 31 Mar 2024: revenue $210.1M, net income -$91.6MQuarter to 30 Jun 2024: revenue $186.7M, net income -$99.2MQuarter to 30 Jun 2024: revenue $186.7M, net income -$99.2MQuarter to 30 Sep 2024: revenue $196.8M, net income -$106.7MQuarter to 30 Sep 2024: revenue $196.8M, net income -$106.7MQuarter to 31 Dec 2024: revenue $213.2M, net income -$65.9MQuarter to 31 Dec 2024: revenue $213.2M, net income -$65.9MQuarter to 31 Mar 2025: revenue $1.2B, net income $866.6MQuarter to 31 Mar 2025: revenue $1.2B, net income $866.6MQuarter to 30 Jun 2025: revenue $178.9M, net income -$64.8MQuarter to 30 Jun 2025: revenue $178.9M, net income -$64.8MQuarter to 30 Sep 2025: revenue $211.0M, net income $15.9MQuarter to 30 Sep 2025: revenue $211.0M, net income $15.9MQuarter to 31 Dec 2025: revenue $164.7M, net income -$135.0MQuarter to 31 Dec 2025: revenue $164.7M, net income -$135.0MQuarter to 31 Mar 2026: revenue $272.6M, net income -$2.8MQuarter to 31 Mar 2026: revenue $272.6M, net income -$2.8MQuarter to 30 Jun 2026: revenue $360.5M, net income $83.5MQuarter to 30 Jun 2026: revenue $360.5M, net income $83.5MQuarter to 30 Sep 2026: revenue $357.8M, net income -$51.7MQuarter to 30 Sep 2026: revenue $357.8M, net income -$51.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.2B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$357.8M-$51.7M
30 Jun 2026$360.5M$83.5M
31 Mar 2026$272.6M-$2.8M
31 Dec 2025$164.7M-$135.0M
30 Sep 2025$211.0M$15.9M
30 Jun 2025$178.9M-$64.8M
31 Mar 2025$1.2B$866.6M
31 Dec 2024$213.2M-$65.9M
30 Sep 2024$196.8M-$106.7M
30 Jun 2024$186.7M-$99.2M
31 Mar 2024$210.1M-$91.6M
31 Dec 2023$307.1M-$155.8M
30 Sep 2023$196.6M-$133.0M
30 Jun 2023$213.8M-$198.9M
31 Mar 2023$220.4M-$139.0M
31 Dec 2022$167.4M-$170.9M
30 Sep 2022$217.1M-$109.3M
30 Jun 2022$165.5M-$152.1M
31 Mar 2022$148.7M-$126.7M
31 Dec 2021$165.2M-$143.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.2B $1.8B
Revenue growthRevenue of the last 12 months compared with the 12 months before. -35% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$106.0M $751.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.40 $8.56
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 12.8% 43.6% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -9.2% 42.3% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – $705.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $2.1B $1.7B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $536.3M $286.3M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.6B (net cash) -$1.4B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.1 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.7 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
PTC TherapeuticsPTCT (this company) $4.7Bloss4.1-35%-9.2%
Dianthus TherapeuticsDNTH $4.8Bloss–––
ErascaERAS $4.8Bloss–––
Cogent BiosciencesCOGT $4.6Bloss–––
LiquidiaLQDA $4.9Bloss7.9+798%-15.1%
Travere TherapeuticsTVTX $4.5Bloss6.9+49%-18.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$5.9M

bought $0, sold $5.9M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-4.3%

359 13F filers vs 375

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

93.9M shares held by 13F filers (30 Sep 2026) of 83.5M outstanding (27 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.3%

7.8M shares sold short (30 Oct 2026) of 83.5M outstanding (27 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.5

7.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.3%

8.3M shares sold short in the report before, 7.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

39%

39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

36

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+70%

$357.8M vs $211.0M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-23%

$2.7M vs $3.4M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$870K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

25

25 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.3×

25 articles in the last 7 days; its usual week has 3.

Price $56.42 on 20 Nov 2026, -26% over 12 months (12-month range $56.42 to $89.55)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $44.4M in the last 12 months (the 12 months before: -$48.7M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 6 published in the last 12 months, -14% on the 12 months before.
Revenue per quarter. Revenue $357.8M in the latest quarter, +70% on a year earlier.
Capital spending per quarter. Capital spending $2.7M in the latest quarter, -23% on a year earlier.
Institutional holders (13F filers). 359 13F filers reported holding it in the latest 13F quarter, +26% on a year earlier.
Federal obligations. Federal obligations: $175K published in the last 12 months (none in the 12 months before).
Lobbying spend. Lobbying spend: $870K published in the last 12 months, +58% on the 12 months before.
Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
4 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 360.5M vs usual 203.9M (2026-06-30); 2.0x the same period a year earlier
30 Jul 20268-K and other filingsDirector or officer change
9 Jun 20268-K and other filingsDirector or officer change
20 Apr 2026Sharp changeLobbying on a new issue: lobbying on a new issue: TRD (2026-03-31)
25 Mar 20268-K and other filingsDirector or officer change
25 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Dec 2025Sharp changeShort interest spike: short interest spike, 12.9M vs usual 5.3M (2025-11-28); 2.8x the same period a year earlier
8 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 1.2B vs usual 211.6M (2025-03-31); 5.6x the same period a year earlier
8 May 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 42 vs usual 27 (2024-12-31); 2.2x the same period a year earlier
7 May 2024Sharp changeLobbying spend jump: lobbying spend jump, 320K vs usual 190K (2024-03-31); 0.6x the same period a year earlier
5 Mar 2024Sharp changeQuarterly revenue change: quarterly revenue change, 307.1M vs usual 182.0M (2023-12-31); 1.8x the same period a year earlier
21 Jan 2024Lobbying filinglobbying engagement terminated (THE MCMANUS GROUP)
18 Jan 2024Lobbying filinglobbying engagement terminated (THORN RUN PARTNERS)
19 Oct 20238-K and other filingsA major agreement ended
1 Oct 2023WARN layoff noticePTC Therapeutics Inc., 308 workers, Plainfield, NJ
1 Oct 2023Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 308)
28 Sep 20238-K and other filingsRestructuring costs announced
29 Aug 2023Sharp changeShort interest spike: short interest spike, 7.2M vs usual 5.2M (2023-08-15); 1.4x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 7.1M vs usual 5.2M (2023-07-31); 1.4x the same period a year earlier
1 Aug 2023Sharp changeShort interest spike: short interest spike, 7.5M vs usual 5.2M (2023-07-14); 1.3x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 7.7M vs usual 5.2M (2023-06-30); 1.5x the same period a year earlier
17 Jul 20238-K and other filingsDirector or officer change
4 Jul 2023Sharp changeShort interest spike: short interest spike, 7.5M vs usual 5.2M (2023-06-15); 1.3x the same period a year earlier
1 Jun 2023WARN layoff noticePTC Therapeutics Inc., 94 workers, Plainfield, NJ
1 Jun 2023Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 94)
23 May 20238-K and other filingsRestructuring costs announced
23 May 20238-K and other filingsDirector or officer change
8 May 20238-K and other filingsPrivate placement of securities (Form D)
18 Apr 20238-K and other filingsDirector or officer change
24 Mar 20238-K and other filingsDirector or officer change
24 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Dec 20228-K and other filingsDirector or officer change
6 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Nov 2022Sharp changeMany funds opening a new position: many funds opening a new position, 43 vs usual 19.50 (2022-09-30); 2.4x the same period a year earlier
1 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 217.1M vs usual 128.8M (2022-09-30); 1.6x the same period a year earlier
9 Jun 20228-K and other filingsDirector or officer change
9 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2022Sharp changeLobbying on a new issue: lobbying on a new issue: TAX (2021-12-31)
10 Jan 20228-K and other filingsDirector or officer change
10 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Dec 2021Sharp changeShort interest spike: short interest spike, 6.9M vs usual 5.0M (2021-12-15); 1.4x the same period a year earlier
Insider net buying (open market)
Month from 1 Jan 2022: -$888K published
Month from 1 Feb 2022: -$1.0M published
Month from 1 Apr 2022: -$479K published
Month from 1 Jun 2022: -$31K published
Month from 1 Aug 2022: -$119K published
Month from 1 Sep 2022: -$65K published
Month from 1 Oct 2022: -$380K published
Month from 1 Jan 2023: -$892K published
Month from 1 Feb 2023: -$245K published
Month from 1 Mar 2023: -$2.0M published
Month from 1 Apr 2023: -$4.7M published
Month from 1 May 2023: -$2.9M published
Month from 1 Jun 2023: -$45K published
Month from 1 Sep 2023: -$465K published
Month from 1 Dec 2023: $199K published
Month from 1 Jan 2024: -$1.2M published
Month from 1 Feb 2024: -$58K published
Month from 1 Apr 2024: -$151K published
Month from 1 May 2024: -$771K published
Month from 1 Jul 2024: -$77K published
Month from 1 Dec 2024: -$10.9M published
Month from 1 Jan 2025: -$1.3M published
Month from 1 Feb 2025: -$1.1M published
Month from 1 Mar 2025: -$5.8M published
Month from 1 Apr 2025: -$179K published
Month from 1 May 2025: -$130K published
Month from 1 Jul 2025: -$124K published
Month from 1 Aug 2025: -$692K published
Month from 1 Sep 2025: -$6.9M published
Month from 1 Oct 2025: -$8.0M published
Month from 1 Nov 2025: -$13.6M published
Month from 1 Dec 2025: -$5.2M published
Month from 1 Jan 2026: -$5.3M published
Month from 1 Feb 2026: -$2.1M published
Month from 1 Mar 2026: -$2.5M published
Month from 1 Apr 2026: -$4.0M published
Month from 1 May 2026: -$1.4M published
Month from 1 Jun 2026: -$8.1M published
Month from 1 Jul 2026: -$7.1M published
Month from 1 Aug 2026: -$4.5M published
Month from 1 Sep 2026: -$2.7M published
Month from 1 Oct 2026: -$1.2M published
Month from 1 Nov 2026: -$174K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 3 published
Quarter from 1 Apr 2022: 6 published
Quarter from 1 Jul 2022: 15 published
Quarter from 1 Oct 2022: 6 published
Quarter from 1 Jan 2023: 4 published
Quarter from 1 Apr 2023: 9 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 5 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 6 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 3 published
Quarter from 1 Jul 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $165.2M, +39% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $148.7M, +26% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $165.5M, +42% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $217.1M, +56% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $167.4M, +1.3% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $220.4M, +48% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $213.8M, +29% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $196.6M, -9.5% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $307.1M, +83% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $210.1M, -4.7% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $186.7M, -13% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $196.8M, +0.1% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $213.2M, -31% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $1.2B, +460% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $178.9M, -4.2% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $211.0M, +7.2% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $164.7M, -23% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $272.6M, -77% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $360.5M, +102% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $357.8M, +70% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $8.7M, +37% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $9.3M, +64% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $8.7M, +9.1% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $5.4M, -7.9% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $8.6M, -1.2% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $10.3M, +10% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $6.2M, -28% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $6.4M, +18% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $5.6M, -35% on a year earlier; public on 1 Mar 2024
Quarter ended 30 Sep 2024: $522K, -92% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $3.8M, -32% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $1.7M; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.3M; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $3.4M, +560% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $2.4M, -37% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $1.2M, -31% on a year earlier; public on 8 May 2026
Quarter ended 30 Sep 2026: $2.7M, -23% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 163; public on 14 Feb 2022
31 Mar 2022 report: 173; public on 16 May 2022
30 Jun 2022 report: 171; public on 15 Aug 2022
30 Sep 2022 report: 197; public on 14 Nov 2022
31 Dec 2022 report: 189; public on 14 Feb 2023
31 Mar 2023 report: 189; public on 15 May 2023
30 Jun 2023 report: 191; public on 14 Aug 2023
30 Sep 2023 report: 164; public on 14 Nov 2023
31 Dec 2023 report: 164; public on 14 Feb 2024
31 Mar 2024 report: 173; public on 15 May 2024
30 Jun 2024 report: 186; public on 14 Aug 2024
30 Sep 2024 report: 197; public on 14 Nov 2024
31 Dec 2024 report: 232; public on 14 Feb 2025
31 Mar 2025 report: 252; public on 15 May 2025
30 Jun 2025 report: 272; public on 14 Aug 2025
30 Sep 2025 report: 286; public on 14 Nov 2025
31 Dec 2025 report: 337; public on 17 Feb 2026
31 Mar 2026 report: 343; public on 15 May 2026
30 Jun 2026 report: 375; public on 14 Aug 2026
30 Sep 2026 report: 359; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2026: $175K published
Lobbying spend
Quarter from 1 Jan 2022: $190K published
Quarter from 1 Apr 2022: $370K published
Quarter from 1 Jul 2022: $200K published
Quarter from 1 Oct 2022: $190K published
Quarter from 1 Jan 2023: $160K published
Quarter from 1 Apr 2023: $570K published
Quarter from 1 Jul 2023: $190K published
Quarter from 1 Oct 2023: $170K published
Quarter from 1 Jan 2024: $170K published
Quarter from 1 Apr 2024: $500K published
Quarter from 1 Jul 2024: $90K published
Quarter from 1 Oct 2024: $90K published
Quarter from 1 Jan 2025: $80K published
Quarter from 1 Apr 2025: $210K published
Quarter from 1 Jul 2025: $120K published
Quarter from 1 Oct 2025: $140K published
Quarter from 1 Jan 2026: $140K published
Quarter from 1 Apr 2026: $390K published
Quarter from 1 Jul 2026: $170K published
Quarter from 1 Oct 2026: $170K published
Workers in WARN layoff notices
Month from 1 Jun 2023: 94 published
Month from 1 Oct 2023: 308 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is workers named in WARN notices at 308 (28 Aug 2023), 3.3× its normal reading.
  • Quarterly revenue change: reported revenue of $360.5M for the quarter ended 30 Jun 2026, 2.0× the same quarter last year Public on 4 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $44.4M in the last 12 months (the 12 months before: -$48.7M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 6 published in the last 12 months, -14% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 9 sales, $5.9M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Mark Elliott BouldingEXEC. VP AND CLOSellplanned in advance (10b5-1); after exercising options2,812$61.88$174KForm 4
16 Oct 2026Michael SchmertzlerDirectorSellplanned in advance (10b5-1)2,500$59.61$149KForm 4
13 Oct 2026Mark Elliott BouldingEXEC. VP AND CLOSellplanned in advance (10b5-1); after exercising options192$64.26$12KForm 4
9 Oct 2026Michael SchmertzlerDirectorSellplanned in advance (10b5-1)2,500$63.39$158KForm 4
7 Oct 2026Mark Elliott BouldingEXEC. VP AND CLOSellplanned in advance (10b5-1); after exercising options2,073$64.06$133KForm 4
2 Oct 2026Steele Glenn Jr Md PhdDirectorSellplanned in advance (10b5-1); after exercising options12,000$65.16$782KForm 4
18 Sep 2026Michael SchmertzlerDirectorSellplanned in advance (10b5-1)20,000$67.49$1.3MForm 4
11 Sep 2026Michael SchmertzlerDirectorSellplanned in advance (10b5-1)20,000$67.59$1.4MForm 4

359 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 51 opened a position, 64 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.14.4M17.2%$932.7M+433K+3.1%
Janus Henderson Group Ltd.6.9M8.22%$445.1M
State Street Corp5.5M6.60%$357.1M+914K+20%
Wellington Management Group LLP5.3M6.32%$341.9M+1.1M+28%
Vanguard Portfolio Management LLC5.0M5.96%$322.5M+50K+1.0%
Vanguard Capital Management LLC3.6M4.33%$234.4M-121K-3.2%
Westfield Capital Management Co LP2.7M3.23%$174.9M+743K+38%
Geode Capital Management, LLC2.1M2.57%$139.2M-59K-2.7%
UBS Group AG1.9M2.25%$121.8M+1.6M+617%
Hood River Capital Management LLC1.8M2.10%$113.8M+18K+1.0%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 7 Sep 2012. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
7 Sep 2012Department of Health and Human ServicesNational Institutes of Health$1.1MDISCOVERY OF ANTIVIRAL AGENTS TARGETING DENGUE VIRAL TRANSLATIONGrantUSAspending

Company events

All 57 company events

In 12 months: 3 major agreements, 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Aug 2026Signed a major agreement8-K
30 Jul 2026Director or officer change8-K
18 Jun 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
9 Jun 2026Director or officer change8-K
25 Mar 2026Director or officer change8-K
29 Dec 2025Signed a major agreement8-K
7 Aug 2025Signed a major agreement8-K
3 Jan 2025Signed a major agreementSame filing: took on new debt8-K

36 open postings; careers site tracked since 21 Nov 2026. Most in Operations & administration 17%, Finance & accounting 8%, Manufacturing & production 6%, Research & science 6%.

PostedJobLocation
21 Nov 2026or earlierAssociate Director, Clinical Data ManagementUSA - New Jersey - Warren
21 Nov 2026or earlierDirector, Clinical Data ManagementUSA - New Jersey - Warren
21 Nov 2026or earlierSenior Scientist, Analytical DevelopmentResearch & scienceUSA - New Jersey - Bridgewater
21 Nov 2026or earlierMedical Value DirectorRemote (United States)
21 Nov 2026or earlierAssociate Director, Clinical SuppliesUSA - New Jersey - Warren
21 Nov 2026or earlierSenior Manager, Clinical Data ManagementUSA - New Jersey - Warren
21 Nov 2026or earlierAssociate Director, Manufacturing Science and Technology – Drug ProductManufacturing & productionUSA - New Jersey - Warren
21 Nov 2026or earlierDirector, Clinical DevelopmentNot stated

Reported lobbying spend: $170K in Q3 2026, $170K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 May 2025NewLMH Strategic Solutionsfor PTC Therapeutics, Inc.Legislation issues impacting PTC Therapeutics, including: H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. MVP Act. Tax Relief for American Families and Workers Act. AmeTaxation, Medicare/Medicaid, Health issuesFiling
31 Dec 2023EndedThe Mcmanus Groupfor PTC Therapeutics Inc.Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act). Education and awareness of rare and ultra rare diseases and patient access to orphan drug; Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.; Issues related to research and development tax amortization in H.R. 2673, S.866 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs ActMedicare/Medicaid, Health issues, TaxationFiling
31 Dec 2023EndedThorn Run Partnersfor PTC Therapeutics, Inc.Issues related to the development of therapies for rare diseases. Increased awareness for AADC deficiency.Health issuesFiling
8 Feb 2021NewThe Mcmanus Groupfor PTC Therapeutics Inc.Update to be completed in AprilHealth issuesFiling
1 Feb 2021NewThorn Run Partnersfor PTC Therapeutics, Inc.Issues related to the development of therapies for rare diseases.Health issuesFiling
31 Dec 2020EndedCGCN Group, LLCfor PTC Therapeutics, Inc.Issues related to healthcare and to the COVID-19 pandemic.Health issuesFiling
6 Oct 2020NewCGCN Group, LLCfor PTC Therapeutics, Inc.Issues related to healthcare and to the COVID-19 pandemic.Health issuesFiling
24 Aug 2020NewPTC Therapeutics, Inc.its own lobbyistsBio pharmaceutical therapies for rare pediatric diseases; Drug development, review and pricing; Issues relating to healthcare and COVID-19 pandemic; Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program Innovation Act (FDASIA)Medicare/Medicaid, Health issues, MEDFiling

Layoff notices

All 2 layoff notices

No notice in 12 months; the latest is dated 1 Sep 2023. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Sep 2023PTC Therapeutics Inc.Plainfield, NJ30827 Dec 2023Notice
1 May 2023PTC Therapeutics Inc.Plainfield, NJ9421 Aug 2023Notice

The 5 newest of 189 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Nov 2022confirmed

Confirmed across sources Institutional holdings and Filings + Financials

PTC Therapeutics (PTCT): reported revenue of $217.1M for the quarter ended 30 Sep 2022, 1.6× the same quarter last year, while it saw 43 13F filers open a new position in the quarter ended 30 Sep 2022, 2.4× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 1 Nov 2022
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2022
2020-09-30: $118.4M2020-12-31: $118.9M2021-03-31: $117.9M2021-06-30: $116.7M2021-09-30: $138.7M2021-12-31: $165.2M2022-03-31: $148.7M2022-06-30: $165.5M2022-09-30: $217.1M
The quarter ended 30 Sep 2022 against the 8 quarters before it. this quarterearliernormal: $128.8M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 1 Nov 2022

PTC Therapeutics reported revenue of $217.1M for the quarter ended 30 Sep 2022, 1.6× the same quarter last year.

This period
$217.1M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$128.8M
Typical spread (median absolute deviation)
$11.5M
How far from its usual level
+5.2
Same quarter last year
$138.7M
History used
3,835 days
2020-09-30: $118.4M2020-12-31: $118.9M2021-03-31: $117.9M2021-06-30: $116.7M2021-09-30: $138.7M2021-12-31: $165.2M2022-03-31: $148.7M2022-06-30: $165.5M2022-09-30: $217.1M
the quarter ended 30 Sep 20228 earlier quartersnormal: $128.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2022

PTC Therapeutics saw 43 13F filers open a new position in the quarter ended 30 Sep 2022, 2.4× the same quarter last year.

This period
43 (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
19.5
Typical spread (median absolute deviation)
4
How far from its usual level
+4.0
Same quarter last year
18
History used
3,287 days
2020-09-30: 212020-12-31: 292021-03-31: 242021-06-30: 152021-09-30: 182021-12-31: 152022-03-31: 232022-06-30: 182022-09-30: 43
the quarter ended 30 Sep 20228 earlier quartersnormal: 19.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

20 Jan 2022confirmed

Confirmed across sources Lobbying and Short interest and volume

PTC Therapeutics (PTCT): had 6.9M shares sold short in the 15 Dec 2021 report, 1.4× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 22 days.

  • Short interest and volume: Short interest spike, became public on 28 Dec 2021
  • Lobbying: Lobbying on a new issue, became public on 20 Jan 2022
2020-12-15: 4.9M2020-12-31: 4.7M2021-01-15: 4.2M2021-01-29: 4.1M2021-02-12: 4.0M2021-02-26: 4.8M2021-03-15: 5.1M2021-03-31: 5.2M2021-04-15: 5.3M2021-04-30: 5.2M2021-05-14: 5.1M2021-05-28: 4.8M2021-06-15: 4.8M2021-06-30: 4.8M2021-07-15: 5.1M2021-07-30: 5.3M2021-08-13: 5.2M2021-08-31: 4.5M2021-09-15: 4.5M2021-09-30: 4.7M2021-10-15: 5.1M2021-10-29: 5.4M2021-11-15: 6.0M2021-11-30: 5.9M2021-12-15: 6.9M
The 15 Dec 2021 report against the 24 reports before it. this reportearliernormal: 5.0M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 28 Dec 2021

PTC Therapeutics had 6.9M shares sold short in the 15 Dec 2021 report, 1.4× the same report last year.

This period
6.9M (the 15 Dec 2021 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
251K
How far from its usual level
+3.9
Same report last year
4.9M
History used
1,447 days
2020-12-15: 4.9M2020-12-31: 4.7M2021-01-15: 4.2M2021-01-29: 4.1M2021-02-12: 4.0M2021-02-26: 4.8M2021-03-15: 5.1M2021-03-31: 5.2M2021-04-15: 5.3M2021-04-30: 5.2M2021-05-14: 5.1M2021-05-28: 4.8M2021-06-15: 4.8M2021-06-30: 4.8M2021-07-15: 5.1M2021-07-30: 5.3M2021-08-13: 5.2M2021-08-31: 4.5M2021-09-15: 4.5M2021-09-30: 4.7M2021-10-15: 5.1M2021-10-29: 5.4M2021-11-15: 6.0M2021-11-30: 5.9M2021-12-15: 6.9M
the 15 Dec 2021 report24 earlier reportsnormal: 5.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 20 Jan 2022

PTC Therapeutics lobbying on a new issue.

New
['TAX']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12635389

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 4 Aug 2026Financials change

    reported revenue of $360.5M for the quarter ended 30 Jun 2026, 2.0× the same quarter last year.

    Same quarter last year: $178.9M; its normal quarter is $203.9M.

    See the evidence
    This period
    $360.5M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $203.9M
    Typical spread (median absolute deviation)
    $21.1M
    How far from its usual level
    +5.0
    Same quarter last year
    $178.9M
    History used
    5,204 days
    2024-06-30: $186.7M2024-09-30: $196.8M2024-12-31: $213.2M2025-03-31: $1.2B2025-06-30: $178.9M2025-09-30: $211.0M2025-12-31: $164.7M2026-03-31: $272.6M2026-06-30: $360.5M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $203.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 30 Jul 2026Filings record

    Director or officer change

  3. 9 Jun 2026Filings record

    Director or officer change

  4. 20 Apr 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4687042
  5. 25 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 25 Mar 2026Filings record

    Director or officer change

  7. 10 Dec 2025Short interest and volume change

    had 12.9M shares sold short in the 28 Nov 2025 report, 2.8× the same report last year.

    Same report last year: 4.6M; its normal report is 5.3M.

    See the evidence
    This period
    12.9M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    5.3M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +5.0
    Same report last year
    4.6M
    History used
    2,891 days
    2024-11-29: 4.6M2024-12-13: 4.6M2024-12-31: 4.2M2025-01-15: 4.2M2025-01-31: 4.2M2025-02-14: 3.7M2025-02-28: 3.8M2025-03-14: 4.3M2025-03-31: 5.4M2025-04-15: 5.5M2025-04-30: 5.0M2025-05-15: 5.2M2025-05-30: 4.8M2025-06-13: 5.1M2025-06-30: 6.0M2025-07-15: 5.8M2025-07-31: 6.0M2025-08-15: 6.5M2025-08-29: 6.6M2025-09-15: 7.3M2025-09-30: 7.1M2025-10-15: 7.8M2025-10-31: 8.3M2025-11-14: 9.4M2025-11-28: 12.9M
    the 28 Nov 2025 report24 earlier reportsnormal: 5.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 8 May 2025Financials change

    reported revenue of $1.2B for the quarter ended 31 Mar 2025, 5.6× the same quarter last year.

    Same quarter last year: $210.1M; its normal quarter is $211.6M.

    See the evidence
    This period
    $1.2B (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $211.6M
    Typical spread (median absolute deviation)
    $11.8M
    How far from its usual level
    +45.6
    Same quarter last year
    $210.1M
    History used
    3,287 days
    2023-03-31: $220.4M2023-06-30: $213.8M2023-09-30: $196.6M2023-12-31: $307.1M2024-03-31: $210.1M2024-06-30: $186.7M2024-09-30: $196.8M2024-12-31: $213.2M2025-03-31: $1.2B
    the quarter ended 31 Mar 20258 earlier quartersnormal: $211.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  9. 8 May 2025Lobbying record

    PTC THERAPEUTICS, INC.: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 May 2025)

  10. 14 Feb 2025Institutional holdings change

    saw 42 13F filers open a new position in the quarter ended 31 Dec 2024, 2.2× the same quarter last year.

    Same quarter last year: 19; its normal quarter is 27.

    See the evidence
    This period
    42 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    27
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +5.0
    Same quarter last year
    19
    History used
    4,110 days
    2022-12-31: 282023-03-31: 252023-06-30: 272023-09-30: 182023-12-31: 192024-03-31: 272024-06-30: 382024-09-30: 282024-12-31: 42
    the quarter ended 31 Dec 20248 earlier quartersnormal: 27

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 6 May 2024Lobbying change

    reported $320K of lobbying spend for the quarter ended 31 Mar 2024, 44% below the same quarter last year.

    Same quarter last year: $570K; its normal quarter is $190K.

    See the evidence
    This period
    $320K (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $190K
    Typical spread (median absolute deviation)
    $20K
    How far from its usual level
    +4.4
    Same quarter last year
    $570K
    History used
    2,739 days
    2022-03-31: $370K2022-06-30: $200K2022-09-30: $190K2022-12-31: $160K2023-03-31: $570K2023-06-30: $190K2023-09-30: $170K2023-12-31: $170K2024-03-31: $320K
    the quarter ended 31 Mar 20248 earlier quartersnormal: $190K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  12. 5 Mar 2024Financials change

    reported revenue of $307.1M for the quarter ended 31 Dec 2023, 1.8× the same quarter last year.

    Same quarter last year: $167.4M; its normal quarter is $182.0M.

    See the evidence
    This period
    $307.1M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $182.0M
    Typical spread (median absolute deviation)
    $24.3M
    How far from its usual level
    +3.5
    Same quarter last year
    $167.4M
    History used
    4,292 days
    2021-12-31: $165.2M2022-03-31: $148.7M2022-06-30: $165.5M2022-09-30: $217.1M2022-12-31: $167.4M2023-03-31: $220.4M2023-06-30: $213.8M2023-09-30: $196.6M2023-12-31: $307.1M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $182.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  13. 21 Jan 2024Lobbying record

    PTC THERAPEUTICS INC.: lobbying engagement terminated (THE MCMANUS GROUP) (dated 31 Dec 2023)

  14. 18 Jan 2024Lobbying record

    PTC THERAPEUTICS, INC.: lobbying engagement terminated (THORN RUN PARTNERS) (dated 31 Dec 2023)

  15. 15 Dec 2023Insiders record

    Gravier Pierre (CHIEF FINANCIAL OFFICER) bought 7,700 shares of PTCT ($198,737) (dated 14 Dec 2023)

  16. 19 Oct 2023Filings record

    A major agreement ended

  17. 1 Oct 2023Layoff notices change

    filed a WARN layoff notice covering 308 workers within 30 days (Plainfield, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    308
    Window
    1 Sep 2023 to 1 Oct 2023

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  18. 1 Oct 2023Layoff notices record

    WARN notice: PTC Therapeutics Inc., 308 workers, Plainfield, NJ (dated 1 Sep 2023)

  19. 28 Sep 2023Filings record

    Restructuring costs announced

  20. 25 Aug 2023Short interest and volume change

    had 7.2M shares sold short in the 15 Aug 2023 report, 1.4× the same report last year.

    Same report last year: 5.1M; its normal report is 5.2M.

    See the evidence
    This period
    7.2M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    5.2M
    Typical spread (median absolute deviation)
    319K
    How far from its usual level
    +3.9
    Same report last year
    5.1M
    History used
    2,055 days
    2022-08-15: 5.1M2022-08-31: 5.0M2022-09-15: 5.4M2022-09-30: 5.0M2022-10-14: 4.7M2022-10-31: 4.8M2022-11-15: 4.7M2022-11-30: 4.5M2022-12-15: 4.7M2022-12-30: 5.2M2023-01-13: 4.7M2023-01-31: 5.8M2023-02-15: 5.0M2023-02-28: 5.0M2023-03-15: 5.4M2023-03-31: 5.4M2023-04-14: 5.2M2023-04-28: 5.2M2023-05-15: 5.4M2023-05-31: 6.3M2023-06-15: 7.5M2023-06-30: 7.7M2023-07-14: 7.5M2023-07-31: 7.1M2023-08-15: 7.2M
    the 15 Aug 2023 report24 earlier reportsnormal: 5.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 10 Aug 2023Short interest and volume change

    had 7.1M shares sold short in the 31 Jul 2023 report, 1.4× the same report last year.

    Same report last year: 5.2M; its normal report is 5.2M.

    See the evidence
    This period
    7.1M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    5.2M
    Typical spread (median absolute deviation)
    266K
    How far from its usual level
    +3.6
    Same report last year
    5.2M
    History used
    2,040 days
    2022-07-29: 5.2M2022-08-15: 5.1M2022-08-31: 5.0M2022-09-15: 5.4M2022-09-30: 5.0M2022-10-14: 4.7M2022-10-31: 4.8M2022-11-15: 4.7M2022-11-30: 4.5M2022-12-15: 4.7M2022-12-30: 5.2M2023-01-13: 4.7M2023-01-31: 5.8M2023-02-15: 5.0M2023-02-28: 5.0M2023-03-15: 5.4M2023-03-31: 5.4M2023-04-14: 5.2M2023-04-28: 5.2M2023-05-15: 5.4M2023-05-31: 6.3M2023-06-15: 7.5M2023-06-30: 7.7M2023-07-14: 7.5M2023-07-31: 7.1M
    the 31 Jul 2023 report24 earlier reportsnormal: 5.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 26 Jul 2023Short interest and volume change

    had 7.5M shares sold short in the 14 Jul 2023 report, 1.3× the same report last year.

    Same report last year: 5.6M; its normal report is 5.2M.

    See the evidence
    This period
    7.5M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    5.2M
    Typical spread (median absolute deviation)
    266K
    How far from its usual level
    +4.4
    Same report last year
    5.6M
    History used
    2,023 days
    2022-07-15: 5.6M2022-07-29: 5.2M2022-08-15: 5.1M2022-08-31: 5.0M2022-09-15: 5.4M2022-09-30: 5.0M2022-10-14: 4.7M2022-10-31: 4.8M2022-11-15: 4.7M2022-11-30: 4.5M2022-12-15: 4.7M2022-12-30: 5.2M2023-01-13: 4.7M2023-01-31: 5.8M2023-02-15: 5.0M2023-02-28: 5.0M2023-03-15: 5.4M2023-03-31: 5.4M2023-04-14: 5.2M2023-04-28: 5.2M2023-05-15: 5.4M2023-05-31: 6.3M2023-06-15: 7.5M2023-06-30: 7.7M2023-07-14: 7.5M
    the 14 Jul 2023 report24 earlier reportsnormal: 5.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 17 Jul 2023Filings record

    Director or officer change

  24. 13 Jul 2023Short interest and volume change

    had 7.7M shares sold short in the 30 Jun 2023 report, 1.5× the same report last year.

    Same report last year: 5.0M; its normal report is 5.2M.

    See the evidence
    This period
    7.7M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    5.2M
    Typical spread (median absolute deviation)
    282K
    How far from its usual level
    +5.0
    Same report last year
    5.0M
    History used
    2,009 days
    2022-06-30: 5.0M2022-07-15: 5.6M2022-07-29: 5.2M2022-08-15: 5.1M2022-08-31: 5.0M2022-09-15: 5.4M2022-09-30: 5.0M2022-10-14: 4.7M2022-10-31: 4.8M2022-11-15: 4.7M2022-11-30: 4.5M2022-12-15: 4.7M2022-12-30: 5.2M2023-01-13: 4.7M2023-01-31: 5.8M2023-02-15: 5.0M2023-02-28: 5.0M2023-03-15: 5.4M2023-03-31: 5.4M2023-04-14: 5.2M2023-04-28: 5.2M2023-05-15: 5.4M2023-05-31: 6.3M2023-06-15: 7.5M2023-06-30: 7.7M
    the 30 Jun 2023 report24 earlier reportsnormal: 5.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 28 Jun 2023Short interest and volume change

    had 7.5M shares sold short in the 15 Jun 2023 report, 1.3× the same report last year.

    Same report last year: 5.6M; its normal report is 5.2M.

    See the evidence
    This period
    7.5M (the 15 Jun 2023 report)
    Normal report (median of 24 earlier)
    5.2M
    Typical spread (median absolute deviation)
    282K
    How far from its usual level
    +4.6
    Same report last year
    5.6M
    History used
    1,994 days
    2022-06-15: 5.6M2022-06-30: 5.0M2022-07-15: 5.6M2022-07-29: 5.2M2022-08-15: 5.1M2022-08-31: 5.0M2022-09-15: 5.4M2022-09-30: 5.0M2022-10-14: 4.7M2022-10-31: 4.8M2022-11-15: 4.7M2022-11-30: 4.5M2022-12-15: 4.7M2022-12-30: 5.2M2023-01-13: 4.7M2023-01-31: 5.8M2023-02-15: 5.0M2023-02-28: 5.0M2023-03-15: 5.4M2023-03-31: 5.4M2023-04-14: 5.2M2023-04-28: 5.2M2023-05-15: 5.4M2023-05-31: 6.3M2023-06-15: 7.5M
    the 15 Jun 2023 report24 earlier reportsnormal: 5.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 1 Jun 2023Layoff notices change

    filed a WARN layoff notice covering 94 workers within 30 days (Plainfield, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    94
    Window
    2 May 2023 to 1 Jun 2023

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  27. 1 Jun 2023Layoff notices record

    WARN notice: PTC Therapeutics Inc., 94 workers, Plainfield, NJ (dated 1 May 2023)

  28. 23 May 2023Filings record

    Director or officer change

  29. 23 May 2023Filings record

    Restructuring costs announced

  30. 8 May 2023Filings record

    Private placement of securities (Form D)

  31. 18 Apr 2023Filings record

    Director or officer change

  32. 24 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 24 Mar 2023Filings record

    Director or officer change

  34. 6 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 6 Dec 2022Filings record

    Director or officer change

  36. 15 Nov 2022several at once

    reported revenue of $217.1M for the quarter ended 30 Sep 2022, 1.6× the same quarter last year, while it saw 43 13F filers open a new position in the quarter ended 30 Sep 2022, 2.4× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 1 Nov 2022

    PTC Therapeutics reported revenue of $217.1M for the quarter ended 30 Sep 2022, 1.6× the same quarter last year.

    This period
    $217.1M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $128.8M
    Typical spread (median absolute deviation)
    $11.5M
    How far from its usual level
    +5.2
    Same quarter last year
    $138.7M
    History used
    3,835 days
    2020-09-30: $118.4M2020-12-31: $118.9M2021-03-31: $117.9M2021-06-30: $116.7M2021-09-30: $138.7M2021-12-31: $165.2M2022-03-31: $148.7M2022-06-30: $165.5M2022-09-30: $217.1M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $128.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2022

    PTC Therapeutics saw 43 13F filers open a new position in the quarter ended 30 Sep 2022, 2.4× the same quarter last year.

    This period
    43 (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    19.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.0
    Same quarter last year
    18
    History used
    3,287 days
    2020-09-30: 212020-12-31: 292021-03-31: 242021-06-30: 152021-09-30: 182021-12-31: 152022-03-31: 232022-06-30: 182022-09-30: 43
    the quarter ended 30 Sep 20228 earlier quartersnormal: 19.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  37. 14 Nov 2022Institutional holdings change

    saw 43 13F filers open a new position in the quarter ended 30 Sep 2022, 2.4× the same quarter last year.

    Same quarter last year: 18; its normal quarter is 19.5.

    See the evidence
    This period
    43 (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    19.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.0
    Same quarter last year
    18
    History used
    3,287 days
    2020-09-30: 212020-12-31: 292021-03-31: 242021-06-30: 152021-09-30: 182021-12-31: 152022-03-31: 232022-06-30: 182022-09-30: 43
    the quarter ended 30 Sep 20228 earlier quartersnormal: 19.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  38. 1 Nov 2022Financials change

    reported revenue of $217.1M for the quarter ended 30 Sep 2022, 1.6× the same quarter last year.

    Same quarter last year: $138.7M; its normal quarter is $128.8M.

    See the evidence
    This period
    $217.1M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $128.8M
    Typical spread (median absolute deviation)
    $11.5M
    How far from its usual level
    +5.2
    Same quarter last year
    $138.7M
    History used
    3,835 days
    2020-09-30: $118.4M2020-12-31: $118.9M2021-03-31: $117.9M2021-06-30: $116.7M2021-09-30: $138.7M2021-12-31: $165.2M2022-03-31: $148.7M2022-06-30: $165.5M2022-09-30: $217.1M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $128.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  39. 9 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 9 Jun 2022Filings record

    Director or officer change

Showing the newest 40 of 87 entries; narrow the window or the kind of data to see older ones.

Not listed: 447 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001070081
Ticker
PTCT
Domain
ptcbio.com
Employer name
PTC THERAPEUTICS, INC. (1 unverified)
Hq location
NJ|WARREN|07059 (1 unverified)
Lobbying client
ptc therapeutics, taylor strategies on behalf of ptc therapeutics
Name
PTC Therapeutics GT, LLC, PTC Therapeutics HD, Inc, PTC Therapeutics, Inc., PTC Therapeutics International Limited and 2 more
Uei
LH7QEHP9V7W1
Wikidata
Q7120959
Wikipedia
PTC Therapeutics
  • DOL H-1B labor condition applications and PERM certifications327 data points1 Oct 2019 to 11 May 2026
  • Federal lobbying disclosures (LDA)17 records, 117 data points1 Jul 2016 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)185 records23 Feb 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1010 data points31 Dec 2010 to 27 Oct 2026
  • SEC Form 4 insider transactions299 records, 664 data points7 Mar 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 63 data points12 Feb 2008 to 3 Nov 2026
  • WARN layoff notices (state labor agencies)2 records, 6 data points1 May 2023 to 1 Sep 2023
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026